CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 572 enrolled
Drug / intervention
Zavicefta Treatmentother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03923426
NCT03923426N/ACompleted

REAL-WORLD OBSERVATIONAL STUDY OF ZAVICEFTA (REGISTERED) (CEFTAZIDIME-AVIBACTAM) TO CHARACTERIZE USE PATTERNS, EFFECTIVENESS AND SAFETY - EZTEAM STUDY

Pfizer·observational·Posted Apr 22, 2019·Updated Jun 21, 2024

In Brief

An observational study evaluating Zavicefta Treatment for Infection. Completed, enrolled 572 participants across 45 sites in 11 countries.

Detailed Summary

This is a non-interventional medical chart review study aiming to examine the treatment patterns, effectiveness, and safety of ceftazidime-avibactam in approximately 12 countries (including but not limited to Austria, France, Germany, Greece, Italy, Spain, United Kingdom, Russia, Argentina, Colombia, Brazil, and Mexico), with possible expansion to other countries as ceftazidime-avibactam is launched. Eligible patients are adults who have been treated with ceftazidime-avibactam in routine practice at participating sites since 01 January, 2018 onwards or since the date of launch in the country if it is posterior to 01 January, 2018. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsInfection
CountriesArgentina, Austria, Brazil, Colombia, France, Germany, Greece, Italy, Russia, Spain, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedApr 22, 2019
Enrollment StartNov 27, 2018
Primary CompletionMar 28, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.2 years ago

Interventions

Zavicefta Treatmentother

Non-interventional - Retrospective Chart Review